<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656043</url>
  </required_header>
  <id_info>
    <org_study_id>XPF-005-101</org_study_id>
    <nct_id>NCT02656043</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel</brief_title>
  <official_title>A Phase 1 and 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, and Exposure of up to 12 Weeks of XPF-005 Treatment in Healthy Volunteers and Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xenon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xenon Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1/2 study enrolling up to 60 healthy volunteers in Phase 1 followed by approximately&#xD;
      150 subjects with acne vulgaris in Phase 2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1/2 study enrolling up to 60 healthy volunteers followed by approximately 150 subjects&#xD;
      with acne vulgaris. Data from Phase 1 stage will be reviewed before progressing to Phase 2.&#xD;
&#xD;
      Phase 1 is an open label study to determine safety, tolerability of XPF-005 topical gel and&#xD;
      exposure of XEN801 (active ingredient). Up to 5 cohorts of 12 healthy volunteers will each&#xD;
      receive different dose volumes of XPF-005 gel or Placebo gel on their face and back for 14 or&#xD;
      21 days. Safety assessments are completed and PK samples are collected at study visits.&#xD;
&#xD;
      Phase 2 is a randomized, double-blind, vehicle-controlled, parallel-group study to determine&#xD;
      safety, tolerability, efficacy of XPF-005 topical gel and exposure of XEN801 (active&#xD;
      ingredient). Approximately 150 subjects with acne vulgaris will apply XPF-005 or matching&#xD;
      placebo gel on their face for 12 weeks. Safety and efficacy assessments are completed and PK&#xD;
      samples are collected at study visits.&#xD;
&#xD;
      Safety assessments include local skin tolerability assessments, vital signs, physical&#xD;
      examination, 12-lead ECG, safety laboratory blood and urine and adverse event reporting.&#xD;
&#xD;
      Efficacy assessments include acne lesion counts and Investigator's Global Assessment (IGA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2015</start_date>
  <completion_date type="Actual">March 17, 2017</completion_date>
  <primary_completion_date type="Actual">February 16, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in acne lesion count</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in acne lesion count</measure>
    <time_frame>Week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Investigator Global Assessment (IGA)</measure>
    <time_frame>Week 4, 8 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>XPF-005</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment: XPF-005 Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: XPF-005 Vehicle Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XPF-005</intervention_name>
    <description>Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.</description>
    <arm_group_label>XPF-005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Vehicle gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Aged between 18 and 50, inclusive&#xD;
&#xD;
          2. Male or female, agree to comply with contraceptive requirements&#xD;
&#xD;
          3. Signed Informed Consent Form&#xD;
&#xD;
          4. Clinical diagnosis of facial acne vulgaris defined as:&#xD;
&#xD;
               -  25 to 75 inflammatory lesions,&#xD;
&#xD;
               -  20 to 120 non-inflammatory lesions, and&#xD;
&#xD;
               -  an IGA score of ≥3&#xD;
&#xD;
          5. Agree to refrain from using any topical acne treatments on the face or any oral acne&#xD;
             treatments. Topical acne treatment that do not have significant or measurable systemic&#xD;
             absorption are permitted for treatment of the back, shoulders, and chest only&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Known sensitivity to any topical or dermal product, including alcohol&#xD;
&#xD;
          2. Female who is breast feeding, pregnant, or planning to become pregnant&#xD;
&#xD;
          3. Any skin condition of the face other than acne vulgaris&#xD;
&#xD;
          4. Two or more active nodular lesions&#xD;
&#xD;
          5. Excessive facial hair that would interfere with the evaluation of safety or with the&#xD;
             diagnosis or assessment of acne vulgaris&#xD;
&#xD;
          6. Use of tanning beds/booths, or excessive sun exposure&#xD;
&#xD;
          7. Use of over-the-counter topical medications for treatment of acne vulgaris on the face&#xD;
             within 14 days of baseline&#xD;
&#xD;
          8. Use of systemic corticosteroids, antibiotics, anti-acne drugs, anti-inflammatory drugs&#xD;
             (NSAIDs are permitted) or prescription topical retinoid use on the face within 28 days&#xD;
             prior the baseline&#xD;
&#xD;
          9. Initiation of hormonal therapy or dose change to hormonal therapy within 12 weeks&#xD;
             prior to baseline.&#xD;
&#xD;
         10. Use of androgen receptor blockers (eg, spironolactone, flutamide) within 12 weeks&#xD;
             prior to baseline&#xD;
&#xD;
         11. Use of oral retinoid (eg, isotretinoin, alitretinoin) within 12 months prior to&#xD;
             baseline and vitamin A supplements &gt;10,000 units/day within 6 months prior to baseline&#xD;
&#xD;
         12. Facial procedures (eg, microdermabrasion, chemical or laser peel) within 8 weeks prior&#xD;
             to baseline&#xD;
&#xD;
         13. Photodynamic therapy within 12 weeks prior to baseline&#xD;
&#xD;
         14. Any other reason that would make the subject, in the opinion of the Investigator or&#xD;
             Sponsor, unsuitable for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xenon Pharmaceuticals Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Xenon Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kirk Barber Research</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2G 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Skin Advancement</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stratica Medical Inc.</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Chih-ho Hong Medical Inc.</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carruthers &amp; Humphrey Clinical Research</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Dermaesthetics</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E 4M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toole Dermatology Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Médicale Nepisiguit</name>
      <address>
        <city>Bathurst</city>
        <state>New Brunswick</state>
        <zip>E2A 4Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SimcoDerm Medical and Surgical Dermatology Center</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermEdge Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research by ICLS</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Dermatology Center</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayview North Dermatology Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2M 4J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. Daniel Schachter Medicine Professional Corporation</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research Inc</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2K4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dre Angélique Gagné-Henley M.D. Inc</name>
      <address>
        <city>Saint-Jérôme</city>
        <state>Quebec</state>
        <zip>J7Z 3B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical Research Corporation</name>
      <address>
        <city>Westmount</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

